BRCA2 and ovarian cancer: Since both parents of the proband were healthy at the age of 73 and given the high prevalence of pathogenic variants in the BRCA1 and BRCA2 genes in ovarian cancer, as well as their significant therapeutic implications, the initial molecular analysis focused on these two genes.